65,437 trials
Cytomegalovirus Infections
Primary: Area Under The Observed Plasma Concentration-Time Curve Between Dosing Intervals AUC(0-tau) — 66.2; 54.1 h*mcg/mL
Healthy Volunteer
Primary: AUC of AZD9291 — 6690; 6269 nM.h
Solid Tumor · Anaplastic Thyroid Cancer
Primary: Maximum Tolerated Dose (MTD) of Cisplatin (Phase I) — 100 mg/m^2
Diabetes · Diabetes Mellitus, Type 1
Primary: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment — -0.40; -0.41; -0.58 percentage of glycosylated haemoglobin
Healthy
Primary: Cmax — 31.27; 35.50 ng/mL — p=0.0082
Amyotrophic Lateral Sclerosis
Primary: ALSFRS-R Total Score at Weeks 0, 2, 4 and 8 — 38.60; 38.60; 38.15; 38.29 scores on a scale — p=0.780
Lymphoma
Primary: Objective Response Rate — .25 proportion of participants
Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants With Molecular Complete Remission at 3 Month Post Transplant — 3 participants
Anemia
Primary: Percentage of Participants Reaching a Hemoglobin (Hb) Value of Greater Than (>) 100 and Less Than (<) 120 Grams Per Liter (gm/L) at Month 6 Before Inclusion — 56.8…
Hyperlipidemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 — 0.10; -1.34; -17.75; -18.57 percent change — p=<0.001
Renal Insufficiency
Primary: AUC (0-t) of Plasma Metformin — 5362; 10411; 8705; 11788 ng*h/mL — p=0.0011
Barrett Esophagus
Primary: The % of Patients With Complete Eradication of Intestinal Metaplasia (IM) at 12 Month — 85; 81.5 percentage of participants
Dysphagia
Primary: Change in Swallow Response Time for 5 cc Thin Liquid Swallows — 2; 2; 4; 3 participants
Pulmonary Hypertension
Primary: Change in Peak Total Pulmonary Resistance Index (TPRI) During Exercise From Baseline to Week 12 — 15.096; 13.954; 15.441; 14.608 mmHg/(L/min/m^2) — p=0.95
Kidney Cancer · Melanoma (Skin) · Metastatic Cancer
Primary: Central Nervous System (CNS) Response Rate by RECIST Criteria — 3; 2 participants